Genetic markers in diagnosis and prediction of relapse in Graves' disease

Experimental and Clinical Endocrinology and Diabetes

Volumn 104, Issue SUPPL. 4, 1996, Pages 98-100

  Badenhoop, K ^a   Donner, H ^a   Braun, J ^a   Siegmund, T ^a   Rau, H ^a   Usadel, K H ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Graves' disease; HLA; Polymorphisms; Relapse prediction

Indexed keywords

HLA DQ ANTIGEN;

CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; DNA POLYMORPHISM; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY;

EID: 0029955146     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1211712     Document Type: Conference Paper

References (7)

1. Badenhoop K, Walfish PG, Rau H, Fischer S, Nicolay A, Bogner U, Schleusener H, Usadel KH: Susceptibility and resistance alleles of human leukocyte antigen (HLA) DQA1 and HLA DQB1 are shared in endocrine autoimmune disease. J Clin Endocrinol Metab 80: 2112-2117, 1995
2. Donner H, Rau H, Walfish PG, Braun J, Siegmund T, Finke R, Usadel KH, Badenhoop K: CTLA4 threonin-17 on chromosome 2q33 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. J Clin Endocrinol Metab (in press) 1996
3. Gribben JG, Freeman GJ, Boussiotis VA, Rennert P, Jellis CL, Greenfield E, Barber M, Restivo VA, Ke X, Gray GS, Nadler LM: CTLA4 mediates antigen-specific apoptosis of human T cells. Proc Natl Acad Sci USA 92: 811-815, 1995
4. Santamaria P, Barbosa JJ, Lindstrom AL, Lemke TA, Goetz FC, Rich SS: HLA-DQB1-associated susceptibility that distinguishes Hashimoto's thyroiditis from Graves' disease in type I diabetic patients. J Clin Endocrinol Metab 78: 878-883, 1994
5. Schleusener H, Schwander J, Holl G, Badenhoop K, Hensen J, Finke R, Schernthaner G, Mayr WR, Kotulla P: Do HLA-DR typing and measurement of TSH-receptor antibodies help in the prediction of the clinical course of Graves' thyrotoxicosis after antithyroid drug treatment? Acta Endocrinol (Copenh.) 115 Suppl. 281: 318-324, 1987
6. Schleusener H, Schwander J, Fischer C, Holle R, Holl G, Badenhoop K, Hensen J, Finke R, Bogner U, Mayr WR, Schernthaner G, Schatz H, Pickardt CR, Kotulla P: Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease. Acta Endocrinol (Copenh.) 120: 689-701, 1989
7. Yanagawa T, Hidaka Y, Guimaraes V, Soliman M, DeGroot LJ: CTLA-4 gene polymorphism associated with Graves' disease in a caucasian population. J Clin Endocrinol Metab 80: 41-45, 1995